Longevity medicine: separating science from marketing

Longevity medicine is having a moment. Clinics are opening in every major city, promising to extend your healthspan, reverse your biological age, and optimize your cellular function. The language is seductive. The price tags are steep. And the evidence behind most of it is thin.

This is not an anti-longevity polemic. Some of the science is genuinely exciting. But the gap between what's being researched and what's being sold is enormous — and patients deserve to know which is which.

What the research actually shows

The science of aging has made remarkable progress in the last two decades. We now understand, at a molecular level, several mechanisms that drive aging: telomere shortening, mitochondrial dysfunction, cellular senescence, epigenetic drift, stem cell exhaustion, and chronic low-grade inflammation. This is real science, published in top journals, advancing rapidly.

The problem is the leap from understanding mechanisms to having interventions that work in humans. That leap has been made for very few things:

• Caloric restriction: The CALERIE trial showed that moderate caloric restriction (25% reduction) over 2 years slowed the pace of biological aging as measured by DunedinPACE. This is the strongest interventional evidence we have.
• Exercise: Both cardiovascular and resistance training are consistently associated with slower aging across multiple biomarkers. The effect is dose-dependent — more exercise, slower aging — with no plateau identified.
• Sleep: Adequate sleep duration and quality are independently associated with slower aging and lower all-cause mortality.
• Not smoking, moderate alcohol: The basics remain the most powerful longevity interventions we have.

Notice what's on this list. It's the same advice your grandmother gave you. The longevity science, for all its sophistication, has mostly confirmed what we already knew — and added precision about why it works at a cellular level.

What's being sold vs. what's been proven

Now compare that evidence base to what longevity clinics typically offer:

• NAD+ infusions: No human RCT showing clinical benefit. Animal data is interesting. Cost: $500–2,000 per session.
• Telomere length testing: High measurement variability. No intervention proven to lengthen telomeres meaningfully. Not actionable.
• Peptide therapy (BPC-157, thymosin): Almost entirely based on animal studies and case reports. No FDA approval. Unknown long-term safety.
• Hyperbaric oxygen: Evidence for wound healing and decompression sickness. Evidence for "anti-aging": a single small trial (n=35) with methodological concerns.
• Exosome therapy: Theoretical promise. Zero randomized trials. The FDA has issued warnings about unapproved exosome products.

What we include — and why only in the LONGEVITY module

At Health Detectors, we've chosen to include a small number of emerging tests in our optional LONGEVITY module. Each one meets a minimum evidence threshold: published validation data, at least one interventional study, and a clear limitation statement.

• DunedinPACE: The only biological aging pace measure validated in a randomized trial (CALERIE). It measures how fast you're aging right now. It responds to intervention. It's repeatable.
• GRAIL Galleri: Multi-cancer early detection via cfDNA. 99.5% specificity. Currently in an NHS trial with 140,000 participants. Not yet guideline-endorsed, but the data is strong enough to offer with appropriate counseling.
• Omega-3 Index: Measures EPA+DHA in red blood cells. Levels ≥8% are associated with significantly lower sudden cardiac death risk. Actionable through diet and supplementation.

Each of these is labeled as "Emerging" (★ evidence grade) with a full Evidence Brief. We never present emerging science as established fact. And we never include it in the core DETECT panel — that's reserved for markers with ★★★ evidence.